Skip to main content

Discovery could lead to neutralizing West Nile virus

Dec. 6, 2018, 10:24 AM

by Bill Snyder

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

Their findings, reported last week in the journal Nature Microbiology, could lead to the first effective treatment for this mosquito-transmitted infection, which sickens 2,500 and kills more than 100 people throughout the country each year, according to the U.S. Centers for Disease Control and Protection (CDC).

“West Nile virus is still an important cause of brain infections in the U.S., and there is very little we can do to help these patients,” said James Crowe Jr., MD, co-corresponding author of the paper and director of the Vanderbilt Vaccine Center.

James Crowe Jr., MD

“It was exciting for us to use our antibody discovery technologies to find naturally occurring human antibodies that can prevent or treat the infection,” he said.

Crowe holds the Ann Scott Carell Chair in the Departments of Pediatrics and Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine. He and his colleagues have isolated human monoclonal antibodies for many pathogenic viruses, including Zika, HIV, dengue, influenza, Ebola, norovirus, respiratory syncytial virus (RSV) and rotavirus.

In the current study, the researchers obtained serum and blood cell samples from 13 adults who were infected by the virus during the 2012 outbreak of West Nile encephalitis in Dallas.

Antibody-producing white blood cells from the subjects were fused to myeloma (cancer) cells to produce fast-growing “factories” of specific, monoclonal antibodies.

One of these antibodies, WNV-86, inhibited the virus in laboratory studies. A single dose of WNV-86 completely protected mice from an otherwise lethal West Nile infection.

Further studies are needed before human testing can begin. But these findings are raising hopes for development of the first effective counter to this potentially dangerous infection.

Researchers from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) and Washington University in St. Louis contributed to the study. Vanderbilt contributors included senior research specialist Nurgun Kose, graduate student Michael Doyle and Gopal Sapparapu, PhD, research assistant professor of Pediatrics.

The study was funded by NIH grants AI073755 and HHSN272201400018C and by the intramural research program of the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases.

Recent Stories from VUMC News and Communications Publications

Our amazing skin

Vanderbilt Medicine

Our amazing skin

Biology and the beat

Vanderbilt Medicine

Biology and the beat

Community care

Vanderbilt Nurse

Community care

Survive and thrive

Hope

Survive and thrive

more